160 related articles for article (PubMed ID: 37590164)
21. Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins.
Yu J; Li H; Fang T; Yun C; Liu X; Xu J; Jiang X; Cai X
J Am Chem Soc; 2023 Aug; 145(34):19107-19119. PubMed ID: 37552887
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like Growth Factor 2 (IGF2)-Fused Lysosomal Targeting Chimeras for Degradation of Extracellular and Membrane Proteins.
Zhang B; Brahma RK; Zhu L; Feng J; Hu S; Qian L; Du S; Yao SQ; Ge J
J Am Chem Soc; 2023 Nov; 145(44):24272-24283. PubMed ID: 37899626
[TBL] [Abstract][Full Text] [Related]
23. Lysosome and related protein degradation technologies.
Zheng H; Li G; Min J; Xu X; Huang W
Drug Discov Today; 2023 Nov; 28(11):103767. PubMed ID: 37708931
[TBL] [Abstract][Full Text] [Related]
24. LAPTM5 promotes lysosomal degradation of intracellular CD3ζ but not of cell surface CD3ζ.
Kawai Y; Ouchida R; Yamasaki S; Dragone L; Tsubata T; Wang JY
Immunol Cell Biol; 2014 Jul; 92(6):527-34. PubMed ID: 24638062
[TBL] [Abstract][Full Text] [Related]
25. Targeted protein degradation in drug development: Recent advances and future challenges.
Song J; Hu M; Zhou J; Xie S; Li T; Li Y
Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
[TBL] [Abstract][Full Text] [Related]
26. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery.
Pei J; Wang G; Feng L; Zhang J; Jiang T; Sun Q; Ouyang L
J Med Chem; 2021 Apr; 64(7):3493-3507. PubMed ID: 33764774
[TBL] [Abstract][Full Text] [Related]
27. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
28. Lysosomes and lysosomal cathepsins in cell death.
Repnik U; Stoka V; Turk V; Turk B
Biochim Biophys Acta; 2012 Jan; 1824(1):22-33. PubMed ID: 21914490
[TBL] [Abstract][Full Text] [Related]
29. Antibody targeting of E3 ubiquitin ligases for receptor degradation.
Marei H; Tsai WK; Kee YS; Ruiz K; He J; Cox C; Sun T; Penikalapati S; Dwivedi P; Choi M; Kan D; Saenz-Lopez P; Dorighi K; Zhang P; Kschonsak YT; Kljavin N; Amin D; Kim I; Mancini AG; Nguyen T; Wang C; Janezic E; Doan A; Mai E; Xi H; Gu C; Heinlein M; Biehs B; Wu J; Lehoux I; Harris S; Comps-Agrar L; Seshasayee D; de Sauvage FJ; Grimmer M; Li J; Agard NJ; de Sousa E Melo F
Nature; 2022 Oct; 610(7930):182-189. PubMed ID: 36131013
[TBL] [Abstract][Full Text] [Related]
30. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway.
Wang K; Yu A; Liu K; Feng C; Hou Y; Chen J; Ma S; Huang L; Dai X
Adv Sci (Weinh); 2023 May; 10(13):e2300288. PubMed ID: 36866919
[TBL] [Abstract][Full Text] [Related]
31. Bifunctional Compounds as Molecular Degraders for Integrin-Facilitated Targeted Protein Degradation.
Zheng J; He W; Li J; Feng X; Li Y; Cheng B; Zhou Y; Li M; Liu K; Shao X; Zhang J; Li H; Chen L; Fang L
J Am Chem Soc; 2022 Dec; 144(48):21831-21836. PubMed ID: 36417563
[TBL] [Abstract][Full Text] [Related]
32. A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation.
Wang Q; Yang X; Yuan R; Shen A; Wang P; Li H; Zhang J; Tian C; Jiang Z; Li W; Dong S
Nat Commun; 2024 Feb; 15(1):1663. PubMed ID: 38396109
[TBL] [Abstract][Full Text] [Related]
33. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation.
Ahn G; Banik SM; Miller CL; Riley NM; Cochran JR; Bertozzi CR
Nat Chem Biol; 2021 Sep; 17(9):937-946. PubMed ID: 33767387
[TBL] [Abstract][Full Text] [Related]
34. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
35. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system.
Ji CH; Kim HY; Lee MJ; Heo AJ; Park DY; Lim S; Shin S; Ganipisetti S; Yang WS; Jung CA; Kim KY; Jeong EH; Park SH; Bin Kim S; Lee SJ; Na JE; Kang JI; Chi HM; Kim HT; Kim YK; Kim BY; Kwon YT
Nat Commun; 2022 Feb; 13(1):904. PubMed ID: 35173167
[TBL] [Abstract][Full Text] [Related]
36. Clearance of plasma PCSK9 via the asialoglycoprotein receptor mediated by heterobifunctional ligands.
Bagdanoff JT; Smith TM; Allan M; O'Donnell P; Nguyen Z; Moore EA; Baird J; Wang S; Subramanian V; Tigani B; Nettleton DO; Monovich LG; Lewis I; Flyer AN; Granda B; Blankenship JW; Barnes-Seeman D; Clairmont KB
Cell Chem Biol; 2023 Jan; 30(1):97-109.e9. PubMed ID: 36626903
[TBL] [Abstract][Full Text] [Related]
37. Low density lipoprotein receptor-related protein: regulation of the plasma membrane proteome.
Gonias SL; Wu L; Salicioni AM
Thromb Haemost; 2004 Jun; 91(6):1056-64. PubMed ID: 15175790
[TBL] [Abstract][Full Text] [Related]
38. A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class II compartments.
Marks MS; Roche PA; van Donselaar E; Woodruff L; Peters PJ; Bonifacino JS
J Cell Biol; 1995 Oct; 131(2):351-69. PubMed ID: 7593164
[TBL] [Abstract][Full Text] [Related]
39. IkappaB is a substrate for a selective pathway of lysosomal proteolysis.
Cuervo AM; Hu W; Lim B; Dice JF
Mol Biol Cell; 1998 Aug; 9(8):1995-2010. PubMed ID: 9693362
[TBL] [Abstract][Full Text] [Related]
40. A conserved ubiquitin- and ESCRT-dependent pathway internalizes human lysosomal membrane proteins for degradation.
Zhang W; Yang X; Chen L; Liu YY; Venkatarangan V; Reist L; Hanson P; Xu H; Wang Y; Li M
PLoS Biol; 2021 Jul; 19(7):e3001361. PubMed ID: 34297722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
